Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages

doi:10.1021/acs.nanolett.1c01210

	Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages
	Chen, Mingshu 1,2; Miao, Yunqiu 2; Qian, Kun 2; Zhou, Xin 2; Guo, Linmiao 2,3; Qiu, Yu 2,3; Wang, Rui 1; Gan, Yong 2,3,4; Zhang, Xinxin 2,3,5
刊名	NANO LETTERS
	2021-07-28
卷号	21 期号:14 页码:6031-6041
关键词	Immunochemotherapy triple-negative breast cancer liposomes tumor-associated macrophages MMP2 response
ISSN号	1530-6984
DOI	10.1021/acs.nanolett.1c01210
通讯作者	Wang, Rui(ellewang@163.com) ; Gan, Yong(ygan@simro.ac.cn) ; Zhang, Xinxin(xinxinzhang@simm.ac.cn)
英文摘要	Triple-negative breast cancer (TNBC) is an aggressive disease with a high recurrence rate and poor outcomes in clinic. In this study, inspired by the enriched innate immune cell type tumor-associated macrophages (TAMs) in TNBC, we proposed a matrix metalloprotease 2 (MMP2) responsive integrated immunochemotherapeutic strategy to deliver paclitaxel (PTX) and anti-CD47 (aCD47) by detachable immune liposomes (ILips). In the TNBC microenvironment, the "two-in-one" ILips facilitated MMP2-responsive release of aCD47 to efficiently polarize M2 macrophages toward the M1 phenotype to enhance phagocytosis against tumor cells and activate the systemic T cell immune response. Together with the immune effect, the detached PTX-loaded liposomes were internalized in MDA-MB-231 cells to synergistically inhibit tumor cell proliferation and metastasis. In the TNBC-bearing mouse model, PTX-loaded ILips demonstrated superior antitumor efficacy against TNBC and inhibited tumor recurrence. Our integrated strategy represents a promising approach to synchronously enhance immune response and tumor-killing effects, improving the therapeutic efficacy against TNBC.
资助项目	National Natural Science Foundation of China[81973250] ; National Natural Science Foundation of China[82025032] ; Chinese Pharmacopoeia Commission[2021Y24] ; State Key Laboratory of Drug Research[SIMM2103ZZ-01] ; Major International Joint Research Project of Chinese Academy of Sciences[153631KYSB20190020]
WOS关键词	POLARIZATION
WOS研究方向	Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
语种	英语
出版者	AMER CHEMICAL SOC
WOS记录号	WOS:000679930400017
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/297999]
专题	中国科学院上海药物研究所
通讯作者	Wang, Rui; Gan, Yong; Zhang, Xinxin
作者单位	1.Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 4.Natl Inst Food & Drug Control, NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipi, Beijing 100050, Peoples R China 5.Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China
推荐引用方式 GB/T 7714	Chen, Mingshu,Miao, Yunqiu,Qian, Kun,et al. Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages[J]. NANO LETTERS,2021,21(14):6031-6041.
APA	Chen, Mingshu.,Miao, Yunqiu.,Qian, Kun.,Zhou, Xin.,Guo, Linmiao.,...&Zhang, Xinxin.(2021).Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages.NANO LETTERS,21(14),6031-6041.
MLA	Chen, Mingshu,et al."Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages".NANO LETTERS 21.14(2021):6031-6041.